ADVERTISEMENT

Aarti Drugs Q3 Results Review - Below Expected Performance: Dolat Capital

Aarti Drugs' Ebitda margin at 10.6%, contracted 354 basis points YoY mainly on account of lower gross margin.

<div class="paragraphs"><p>Aarti Drugs Ltd. (Source:  Company website)</p></div>
Aarti Drugs Ltd. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More